Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18711819 | 0.89 | SPR (0.80) | SPR | |
| SCHEMBL18702455 | 0.85 | SPR (1.00) | SPR | |
| SCHEMBL18689722 | 0.85 | SPR (1.00) | SPR | |
| SCHEMBL18702147 | 0.85 | SPR (1.00) | SPR | |
| SCHEMBL18702459 | 0.82 | SPR (1.00) | SPR | |
| SCHEMBL18702333 | 0.81 | SPR (1.00) | SPR | |
| SCHEMBL18702491 | 0.81 | SPR (1.00) | SPR | |
| SCHEMBL18702327 | 0.80 | SPR (1.00) | SPR | |
| SCHEMBL18702461 | 0.80 | SPR (1.00) | SPR | |
| SCHEMBL18702326 | 0.80 | SPR (1.00) | SPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3356345-B1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-08 | — | — | EP | disclosed |
| EP-3356345-B1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-08 | — | — | EP | disclosed |
| EP-3356345-A1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2018-08-08 | — | — | EP | disclosed |
| US-9963462-B2 | Sepiapterin reductase inhibitors | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2018-05-08 | — | — | US | disclosed |
| US-9963462-B2 | Sepiapterin reductase inhibitors | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2018-05-08 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | SPR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.